Research Analysts Issue Forecasts for TRVI FY2026 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for Trevi Therapeutics in a research note issued on Wednesday, March 18th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.54) per share for the year, down from their previous estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.66) EPS and FY2029 earnings at ($0.05) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04.

Several other equities analysts have also commented on TRVI. Stifel Nicolaus upped their target price on Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, December 19th. JonesTrading decreased their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $21.60.

Trevi Therapeutics Stock Up 0.1%

TRVI stock opened at $10.70 on Friday. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -33.44 and a beta of 0.94. Trevi Therapeutics has a 52-week low of $4.85 and a 52-week high of $14.39. The stock’s fifty day simple moving average is $11.14 and its 200-day simple moving average is $10.93.

Hedge Funds Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Trevi Therapeutics during the 4th quarter worth about $50,000. Seven Fleet Capital Management LP purchased a new position in Trevi Therapeutics in the fourth quarter valued at approximately $89,000. Invesco Ltd. raised its holdings in Trevi Therapeutics by 3.3% in the fourth quarter. Invesco Ltd. now owns 498,926 shares of the company’s stock valued at $6,247,000 after buying an additional 15,856 shares during the period. KVP Capital Advisors LP acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $5,183,000. Finally, XTX Topco Ltd acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $1,049,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics News Roundup

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham & Company raised its price target for TRVI to $24 and maintained a buy rating — a bullish signal that upgrades upside expectations and likely supports demand for the stock. Read More.
• Positive Sentiment: Trevi reported Q4 EPS of -$0.06, beating consensus (about -$0.096). The earnings beat helped the shares gap up on the report, which appears to be the immediate catalyst for buying interest. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed its buy rating and $19 target for TRVI, which reinforces institutional positive sentiment following the quarter. Read More.
• Positive Sentiment: HC Wainwright continues to model growth for Trevi (multiple quarterly EPS estimates) and maintains a $21 target and Buy stance — analyst modeling and multi-quarter estimates provide a favorable medium-term narrative. Read More.
• Neutral Sentiment: Investors can review the full Q4 2025 earnings call and transcript for details on guidance, pipeline progress and cash runway; the beat was small, so follow-up commentary will determine sustained momentum. Read More.
• Neutral Sentiment: Analyst roundups and broader healthcare coverage pieces summarize opinions on TRVI but add less immediate directional pressure than direct target changes or company results. Read More.
• Negative Sentiment: Morgan Stanley trimmed its target from $19 to $18 (still “overweight”), lowering near-term expectations; that cut tempers some of the bullish commentary and could cap upside if other houses follow. Read More.
• Negative Sentiment: One report noted JonesTrading lowered its target from $25 to $24 (still a buy) — while still positive, downward target revisions reduce the size of potential upgrades and can limit momentum. Read More.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.